C-Path Launches Revamped Website to Enhance Collaborations in Drug Development

TUCSON, Ariz., February 15, 2024 — Critical Path Institute (C-Path) today officially launched its newly revamped website, designed to further enhance collaborative efforts in the drug development ecosystem. The upgraded online platform embodies a crisp, modern, and intuitive approach, reflecting C-Path’s commitment to accelerating the development of novel medical innovations through optimal data management, actionable biomarkers, advanced modeling and analytics, and clinically meaningful endpoints, all with a focus on regulatory science.

Constructed to be intuitive and mobile-friendly, the new website ensures that visitors can readily access critical information and resources, from anywhere. This enhancement is a testament to C-Path’s dedication to innovation and accessibility in the digital age, ensuring that the platform’s wealth of resources is readily available for all users, reflecting two decades’ worth of commitment to excellence in accelerating drug development for people with unmet medical needs.

“In the spirit of innovation and collaboration that has always been the cornerstone of our efforts at C-Path, the launch of our new website represents a pivotal advancement in our mission to accelerate the development of new therapies,” said C-Path President and COO Kristen Swingle, M.S. “By enhancing our online presence, we’re making sure that our collective endeavors to positively contribute to public health are more accessible and impactful than ever before. We encourage visitors from across the drug development spectrum to explore the new site and join us in our mission to bring about safer, more effective treatments.”

New c-path.org

Visitors to the C-Path website can now easily find information related to its activities. Navigation has been improved, with C-Path’s core competencies highlighted and interweaved within its collaborations — grouped under relevant and intuitive categories for visitors, such as Pediatrics, Rare and Orphan Diseases, and Neuroscience. Additionally, each collaboration is identified based on how it supports C-Path’s overarching mission to accelerate drug development, making it simpler for users to navigate through the vast array of tools, platforms, solutions, and initiatives designed to address unmet needs in the drug development process.

The website also reinforces C-Path’s impactful contributions across various specific therapeutic areas, including Alzheimer’s disease, Parkinson’s disease, rare diseases, and many others. By providing access to integrated patient-level databases, facilitating the regulatory qualification of biomarkers, and developing clinical trial simulators, C-Path underscores its vital role in modernizing the drug development process to bring safer and more effective therapies to patients faster.

The revamped website, with its clean design, modern interface, and intuitive functionality, serves as a central hub for its stakeholders in the therapeutic development ecosystem to access the tools necessary to address unmet needs in the development of safe and effective therapies.

Visit the new C-Path website at c-path.org to explore the enhanced features and learn more about how C-Path is setting new standards in the advancement of drug development and how you can help support C-Path’s mission.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.


Roxan Triolo Olivas

Kissy Black